

Victoza[®] (liraglutide) – First-time A-rated generic launch

- On December 24, 2024, [Hikma launched](#) an [AP-rated](#) generic version of Novo Nordisk's [Victoza \(liraglutide\)](#) injection.
 - Previously, [Teva launched](#) an authorized brand alternative of Victoza.
- Hikma's generic Victoza and Novo Nordisk's brand Victoza are approved as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients aged 10 years and older with type 2 diabetes mellitus (T2DM).
- Brand Victoza is also approved to reduce the risk of major adverse cardiovascular (CV) events (CV death, non-fatal myocardial infarction, or non-fatal stroke) in adults with T2DM and established CV disease.
- Victoza carries a boxed warning for risk of thyroid C-cell tumor.
- The wholesale acquisition cost (WAC) for Hikma's generic Victoza is \$480 for the 2-pen package and \$720 for the 3-pen package. This is ~12% lower cost than brand Victoza.



At Optum, we help create a healthier world, one insight, one connection, one person at a time. All Optum trademarks and logos are owned by Optum, Inc., in the U.S. and other jurisdictions. All other trademarks are the property of their respective owners. This document contains information that is considered proprietary to Optum Rx and should not be reproduced without the express written consent of Optum Rx. RxNews[®] is published by the Optum Rx Clinical Services Department.